13925-08-1

Usage

Uses

Used in Flavor Industry:
2-Methyl-5-vinylpyrazine, 99% is used as a flavoring agent for its characteristic roasted, nutty, and green notes. It is particularly useful in enhancing the flavor of coffee, roasted nuts, and other similar products.
Used in Pharmaceutical Industry:
2-Methyl-5-vinylpyrazine, 99% is used as an intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and reactivity.
Used in Chemical Research:
2-Methyl-5-vinylpyrazine, 99% is used as a research compound for studying its chemical properties, reactions, and potential applications in various fields, including materials science and drug discovery.

Preparation

By methylation of the Mannich base obtained by reacting formaldehyde and dimethylamine with dimethyl-2,5-pyrazine, followed by the Hoffman degradation

InChI:InChI=1/C7H8N2/c1-3-7-5-8-6(2)4-9-7/h3-5H,1H2,2H3

Upstream product

• 98006-90-7 2-bromo-5-methyl-pyrazine 
• 7486-35-3 tri-n-butyl(vinyl)tin 
• 50-99-7 D-glucose 
• 59-51-8 DL-methionine 
• 492-62-6 alpha-D-glucopyranose 
• 56-40-6 glycine 
• 556-50-3 glycylglycine 
• 5051-06-9 (S)-6-Amino-2-((S)-2-amino-propionylamino)-hexanoic acid 
• 997-62-6 Gly-L-Lys-OH 
• 56-87-1 L-lysine 
• 72-18-4 L-valine 
• 56-41-7 L-alanin 
• 50-00-0 formaldehyd 

Relevant academic research and scientific papers

Comparison of pyrazines formation in methionine/glucose and corresponding Amadori rearrangement product model

The generation of pyrazines in a binary methionine/glucose (Met/Glc) mixture and corresponding methionine/glucose-derived Amadori rearrangement product (MG-ARP) was studied. Quantitative analyses of pyrazines and methional revealed that MG-ARP generated more methional compared to Met/Glc, whereas lower content and fewer species of pyrazines were observed in the MG-ARP model. Comparing the availability of α-dicarbonyl compounds generated from the Met/Glc model, methylglyoxal (MGO) was a considerably effective α-dicarbonyl compound for the formation of pyrazines during MG-ARP degradation, but glyoxal (GO) produced from MG-ARP did not effectively participate in the corresponding formation of pyrazines due to the asynchrony on the formation of GO and recovered Met. Diacetyl (DA) content was not high enough to form corresponding pyrazines in the MG-ARP model. The insufficient interaction of precursors and rapid drops in pH limited the formation of pyrazines during MG-ARP degradation. Increasing reaction temperature could reduce the negative inhibitory effect by promoting the content of precursors.

Impact of the N-terminal amino acid on the formation of pyrazines from peptides in maillard model systems

Only a minor part of Maillard reaction studies in the literature focused on the reaction between carbohydrates and peptides. Therefore, in continuation of a previous study in which the influence of the peptide C-terminal amino acid was investigated, this study focused on the influence of the peptide N-terminal amino acid on the production of pyrazines in model reactions of glucose, methylglyoxal, or glyoxal. Nine different dipeptides and three tripeptides were selected. It was shown that the structure of the N-terminal amino acid is determinative for the overall pyrazine production. Especially, the production of 2,5(6)-dimethylpyrazine and trimethylpyrazine was low in the case of proline, valine, or leucine at the N-terminus, whereas it was very high for glycine, alanine, or serine. In contrast to the alkyl-substituted pyrazines, unsubstituted pyrazine was always produced more in the case of experiments with free amino acids. It is clear that different mechanisms must be responsible for this observation. This study clearly illustrates the capability of peptides to produce flavor compounds such as pyrazines.

AZEPINO [4, 5-B] INDOLES AND METHODS OF USE

This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1, 2,3,4,5, 6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided.

Diarylbutyl octahydropyrazinopyrimidinones and methods of medical treatment using them

2,3,4,7,8,9-Substituted octahydropyrazinopyrimidinones and acid addition salts thereof. A process for the preparation of said compounds. A pharmaceutical composition comprising such a compound and a conventional carrier. A process for the preparation of said composition. Method of medical treatment of human beings and animals using such compounds.